The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

There are many purposes that spots and stripes serve in nature, but how they form has been more of a mystery to scientists.

Vertex stock dipped late Monday on a mixed third-quarter report, with the lion's share of its sales beat coming from its ...

In the U.S., revenue climbed 15%, to $1.98 billion, helped by strong demand and higher pricing for its cystic-fibrosis drugs, the company said. Its Casgevy and Journavx drugs, which treat severe ...

Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...

Given the Danes are among Europe's most prolific coffee drinkers, chances are nearly every staff member will visit the one breakout area at FC Midtjylland's training complex several times daily. While ...

Abstract: The graph coloring problem involves coloring the nodes of a graph using the minimum number of colors such that no two adjacent nodes share the same color. This NP-hard problem has various ...

Vertex Pharmaceuticals recently announced that the FDA has granted Breakthrough Therapy Designation to povetacicept for IgA nephropathy, along with key clinical advancements in its kidney disease ...

Vertex has begun a full-court press for Journavx, enlisting NBA All-Star Jayson Tatum to discuss his use of the new non-opioid painkiller while recovering from a serious injury. Tatum ruptured his ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline setbacks. In August 2025, Vertex’s phase II study on the oral formulation of ...